<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40666694</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1176-6336</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Therapeutics and clinical risk management</Title><ISOAbbreviation>Ther Clin Risk Manag</ISOAbbreviation></Journal><ArticleTitle>Exploring the Complementary Role of Traditional Chinese Medicine in Enhancing Percutaneous Coronary Intervention Outcomes: Mechanisms, Benefits, and Future Research Directions.</ArticleTitle><Pagination><StartPage>1069</StartPage><EndPage>1083</EndPage><MedlinePgn>1069-1083</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/TCRM.S511630</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease (CAD), yet opportunities remain to improve clinical outcomes, symptom management, and long-term prognosis. Traditional Chinese Medicine (TCM), with its multi-target and multi-pathway mechanisms, offers a promising complementary approach to enhance PCI efficacy.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic search was conducted in PubMed and Web of Science using the terms: ("Percutaneous Coronary Intervention" AND "Traditional Chinese Medicine") and ("Percutaneous Coronary Intervention" AND "Chinese Herbal Drugs"). Randomized controlled trials (RCTs) with &#x2265;100 participants were included to evaluate TCM's clinical efficacy in PCI. Pharmacological studies were also reviewed to explore underlying mechanisms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A review of 20 RCTs showed that TCM plays multiple roles in CAD treatment during PCI. Specific interventions such as Danhong Injection, Tongxinluo Capsule, and Shenzhu Guanxin Granule were found to alleviate angina symptoms, restore cardiac function, reduce cardiac biomarkers, prevent no-reflow/slow-flow phenomena, inhibit in-stent restenosis, and improve prognosis while reducing complications. Mechanistically, TCM exerts its effects through antiplatelet action, anti-inflammation, inhibition of smooth muscle proliferation, vasodilation, microcirculation improvement, and endothelial protection.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This systematic review highlights the complementary benefits of TCM in PCI for CAD patients. Effective interventions such as Danhong Injection and Tongxinluo Capsule contribute to symptom relief, cardiac function restoration, restenosis inhibition, and prognosis improvement. These benefits are linked to TCM's multi-target mechanisms, including anti-inflammatory and antiplatelet effects. Future high-quality studies are needed to further validate these findings and refine clinical applications.</AbstractText><CopyrightInformation>&#xa9; 2025 Zheng et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Sidao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, 100039, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Ther Clin Risk Manag</MedlineTA><NlmUniqueID>101253281</NlmUniqueID><ISSNLinking>1176-6336</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical efficacy</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">mechanisms of action</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">traditional Chinese medicine</Keyword></KeywordList><CoiStatement>All authors declare that there are no conflicts of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>11</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40666694</ArticleId><ArticleId IdType="pmc">PMC12260233</ArticleId><ArticleId IdType="doi">10.2147/TCRM.S511630</ArticleId><ArticleId IdType="pii">511630</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu J. The population-based strategy for cardiovascular disease prevention and control in China. <i>Zhonghua Xin Xue Guan Bing Za Zhi</i>. 2022;50(12):1138&#x2013;1141. doi: 10.3760/cma.j.cn112148-20220907-00676
</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20220907-00676</ArticleId><ArticleId IdType="pubmed">36517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Haji AM, Toloui A, Ahmadzadeh K, Madani NA, Yousefifard M. Premature coronary artery disease and plasma levels of interleukins; a systematic scoping review and meta-analysis. <i>Arch Acad Emerg Med</i>. 2022;10:e51.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9397602</ArticleId><ArticleId IdType="pubmed">36033992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian G, Sun Y, Liu S, et al. Therapeutic effects of Wenxin Keli in cardiovascular diseases: an experimental and mechanism overview. <i>Front Pharmacol</i>. 2018;9:1005. doi: 10.3389/fphar.2018.01005
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01005</ArticleId><ArticleId IdType="pmc">PMC6134428</ArticleId><ArticleId IdType="pubmed">30233380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Zeng Z, Wen H, et al. Application of genome-wide association studies in coronary artery disease. <i>Curr Pharm Des</i>. 2019;25(40):4274&#x2013;4286. doi: 10.2174/1381612825666191105125148
</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666191105125148</ArticleId><ArticleId IdType="pubmed">31692429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Lv Q, Li Y, et al. Gensini score values for predicting periprocedural myocardial infarction: an observational study analysis. <i>Medicine</i>. 2022;101(29):e29491. doi: 10.1097/MD.0000000000029491
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000029491</ArticleId><ArticleId IdType="pmc">PMC9302281</ArticleId><ArticleId IdType="pubmed">35866829</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Liu Y, Guan B, et al. Comprehensive assessment of the left ventricular systolic function in the elderly with acute myocardial infarction using echocardiography. <i>Int J Gen Med</i>. 2022;15:1437&#x2013;1445. doi: 10.2147/IJGM.S348594
</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S348594</ArticleId><ArticleId IdType="pmc">PMC8846626</ArticleId><ArticleId IdType="pubmed">35177928</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lv L, Ruan M, et al. Qin Huang formula enhances the effect of Adriamycin in B-cell lymphoma via increasing tumor infiltrating lymphocytes by targeting toll-like receptor signaling pathway. <i>BMC Complement Med Ther</i>. 2022;22(1):185. doi: 10.1186/s12906-022-03660-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12906-022-03660-8</ArticleId><ArticleId IdType="pmc">PMC9272877</ArticleId><ArticleId IdType="pubmed">35818037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirdeeva Y, Fedorova O, Daks A, Barlev N, Shuvalov O. How should the worldwide knowledge of traditional cancer healing be integrated with herbs and mushrooms into modern molecular pharmacology?
<i>Pharmaceuticals</i>. 2022;15(7). doi: 10.3390/ph15070868</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15070868</ArticleId><ArticleId IdType="pmc">PMC9320176</ArticleId><ArticleId IdType="pubmed">35890166</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YY, Wang H, Zhang YY. Macrophage migration inhibitory factor gene rs755622 G/C polymorphism and coronary artery disease: a meta-analysis of 8488 participants. <i>Front Cardiovasc Med</i>. 2022;9:959028. doi: 10.3389/fcvm.2022.959028
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.959028</ArticleId><ArticleId IdType="pmc">PMC9515403</ArticleId><ArticleId IdType="pubmed">36186991</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadas S, Coyle D. Barriers to and facilitators of technology in cardiac rehabilitation and self-management: systematic qualitative grounded theory review. <i>J Med Internet Res</i>. 2020;22(11):e18025. doi: 10.2196/18025
</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/18025</ArticleId><ArticleId IdType="pmc">PMC7688378</ArticleId><ArticleId IdType="pubmed">33174847</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J, Harper MT. Protease-activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model. <i>Res Pract Thromb Haemost</i>. 2022;6(3):e12703. doi: 10.1002/rth2.12703
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12703</ArticleId><ArticleId IdType="pmc">PMC9001860</ArticleId><ArticleId IdType="pubmed">35434469</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Fang Y, Gao B, et al. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease. <i>BMC Cardiovasc Disord</i>. 2022;22(1):474. doi: 10.1186/s12872-022-02932-y
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-022-02932-y</ArticleId><ArticleId IdType="pmc">PMC9644478</ArticleId><ArticleId IdType="pubmed">36348286</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. <i>Cochrane Database Syst Rev</i>. 2017;1:D10447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464734</ArticleId><ArticleId IdType="pubmed">28079254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohm I, Kretzschmar D, Pistulli R, et al. Impact of ivabradine on inflammatory markers in chronic heart failure. <i>J Immunol Res</i>. 2016;2016:6949320. doi: 10.1155/2016/6949320
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6949320</ArticleId><ArticleId IdType="pmc">PMC5086393</ArticleId><ArticleId IdType="pubmed">27822484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang Z, Li B, Yang P. Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1. <i>BMC Cardiovasc Disord</i>. 2020;20(1):293. doi: 10.1186/s12872-020-01562-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01562-6</ArticleId><ArticleId IdType="pmc">PMC7294645</ArticleId><ArticleId IdType="pubmed">32539722</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh CY, Parlow S, Di Santo P, et al. Utility of a smartphone application in assessing palmar circulation prior to radial artery harvesting for coronary artery bypass grafting: rationale and design of the randomised CAPITAL iRADIAL-CABG trial. <i>BMJ Open</i>. 2022;12(4):e55580. doi: 10.1136/bmjopen-2021-055580</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-055580</ArticleId><ArticleId IdType="pmc">PMC8995949</ArticleId><ArticleId IdType="pubmed">35396289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Choi DW, Kim C, et al. Long-term beta-blocker therapy in patients with stable coronary artery disease after percutaneous coronary intervention. <i>Front Cardiovasc Med</i>. 2022;9:878003. doi: 10.3389/fcvm.2022.878003
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.878003</ArticleId><ArticleId IdType="pmc">PMC9152083</ArticleId><ArticleId IdType="pubmed">35656394</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki M, Park SJ, Dauerman HL, et al. Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nat Rev Cardiol</i>. 2022;19(10):684&#x2013;703. doi: 10.1038/s41569-022-00687-9
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-022-00687-9</ArticleId><ArticleId IdType="pmc">PMC9982688</ArticleId><ArticleId IdType="pubmed">35449407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuramitsu S, Kazuno Y, Sonoda S, et al. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. <i>Eur Heart J Cardiovasc Imaging</i>. 2016;17(1):34&#x2013;40. doi: 10.1093/ehjci/jev203
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jev203</ArticleId><ArticleId IdType="pmc">PMC4684161</ArticleId><ArticleId IdType="pubmed">26333375</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengchata P, Pongakasira R, Wongsawangkit N, Phichaphop A, Wongpraparut N. Characteristics and pattern of calcified nodule and/or nodular calcification detected by intravascular ultrasound on the device-oriented composite endpoint (DoCE) in patients with heavily calcified lesions who underwent rotational atherectomy-assisted percutaneous coronary intervention. <i>J Interv Cardiol</i>. 2023;2023:6456695. doi: 10.1155/2023/6456695
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/6456695</ArticleId><ArticleId IdType="pmc">PMC9884160</ArticleId><ArticleId IdType="pubmed">36721852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoare D, Tsiamis A, Marland J, et al. Predicting cardiovascular stent complications using self-reporting biosensors for noninvasive detection of disease. <i>Adv Sci</i>. 2022;9(15):e2105285. doi: 10.1002/advs.202105285</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202105285</ArticleId><ArticleId IdType="pmc">PMC9130883</ArticleId><ArticleId IdType="pubmed">35322587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Shen H, Mao H, Yu F, Wang H, Zheng J. Shock index on admission is associated with coronary Slow/No reflow in patients with acute myocardial infarction undergoing emergent percutaneous coronary intervention. <i>J Interv Cardiol</i>. 2019;2019:7873468. doi: 10.1155/2019/7873468
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7873468</ArticleId><ArticleId IdType="pmc">PMC6739769</ArticleId><ArticleId IdType="pubmed">31772546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A, Chen Q. Segmentation algorithm-based safety analysis of cardiac computed tomography angiography to evaluate doctor-nurse-patient integrated nursing management for cardiac interventional surgery. <i>Comput Math Methods Med</i>. 2022;2022:2148566. doi: 10.1155/2022/2148566
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2148566</ArticleId><ArticleId IdType="pmc">PMC9095376</ArticleId><ArticleId IdType="pubmed">35572833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu JJ, Ali H, Cheng BC, et al. Extracorporeal shock wave treatment attenuated left ventricular dysfunction and remodeling in mini-pig with cardiorenal syndrome. <i>Oncotarget</i>. 2017;8(33):54747&#x2013;54763. doi: 10.18632/oncotarget.18287
</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18287</ArticleId><ArticleId IdType="pmc">PMC5589618</ArticleId><ArticleId IdType="pubmed">28903379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu FY, Yan X, Zhang Z, Xiong XJ, Wang J, Liu HX. Features of complementary and alternative medicine use by patients with coronary artery disease in Beijing: a cross-sectional study. <i>BMC Complement Altern Med</i>. 2013;13(1):287. doi: 10.1186/1472-6882-13-287
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-13-287</ArticleId><ArticleId IdType="pmc">PMC3815283</ArticleId><ArticleId IdType="pubmed">24160843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Ma X, Kong Z, Yang C. Adjunctive effect and safety of Chinese herbal medicine in patients with coronary artery disease undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Altern Ther Health Med</i>. 2024;30(5):155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">37917887</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. <i>J Ethnopharmacol</i>. 2012;141(2):578&#x2013;583. doi: 10.1016/j.jep.2011.08.071
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2011.08.071</ArticleId><ArticleId IdType="pubmed">21924336</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Guo S, Li F, et al. Acupuncture as an adjunctive treatment for angina due to coronary artery disease: a meta-analysis. <i>Med Sci Monit</i>. 2019;25:1263&#x2013;1274. doi: 10.12659/MSM.913379
</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.913379</ArticleId><ArticleId IdType="pmc">PMC6390455</ArticleId><ArticleId IdType="pubmed">30770700</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu DP, Wu HL, Lan TH, et al. Effect of Shenzhu Guanxin Recipe () on patients with angina pectoris after percutaneous coronary intervention: a prospective, randomized controlled trial. <i>Chin J Integr Med</i>. 2015;21(6):408&#x2013;416. doi: 10.1007/s11655-015-2040-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-015-2040-6</ArticleId><ArticleId IdType="pubmed">26063318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YG, Qi J, Zheng G. Clinical efficacy evaluation of shuangshen tongguan capsule on acute myocardial infarction patients after direct percutaneous coronary intervention. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2012;32(12):1602&#x2013;1606.
</Citation><ArticleIdList><ArticleId IdType="pubmed">23469595</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Chen Y, Zhi G, et al. Myocardial protective effect of Danhong Injection evaluated by velocity vector imaging in patients undergoing percutaneous coronary intervention. <i>Zhonghua Yi Xue Za Zhi</i>. 2014;94(30):2346&#x2013;2349.
</Citation><ArticleIdList><ArticleId IdType="pubmed">25399975</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Y, Pan Y, Gao Y, et al. Effect of Danhong injection combined with Naoxintong tablets on prognosis and inflammatory factor expression in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Acta Cardiol Sin</i>. 2015;31(4):301&#x2013;307. doi: 10.6515/acs20150502a
</Citation><ArticleIdList><ArticleId IdType="doi">10.6515/acs20150502a</ArticleId><ArticleId IdType="pmc">PMC4804926</ArticleId><ArticleId IdType="pubmed">27122886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZL, Zhang PY, Liu M, et al. Preventive effect of Fangshuan capsule on PCI-induced myocardial damage and vascular endo- thelial injury in patients with unstable angina pectoris. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2016;36(11):1295&#x2013;1299.
</Citation><ArticleIdList><ArticleId IdType="pubmed">30641618</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HY, Wang W, Shi DZ, et al. Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention. <i>Chin J Integr Med</i>. 2012;18(6):423&#x2013;430. doi: 10.1007/s11655-012-0966-5
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-012-0966-5</ArticleId><ArticleId IdType="pubmed">22382523</ArticleId></ArticleIdList></Reference><Reference><Citation>X A, Li Z, Luo W, Chai J. Long-term compound danshen dripping pills therapy reduces the no-reflow phenomenon in nondiabetes mellitus patients after primary percutaneous coronary intervention for acute myocardial infarction. <i>Ann Palliat Med</i>. 2020;9(3):1144&#x2013;1151. doi: 10.21037/apm-20-1056
</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-20-1056</ArticleId><ArticleId IdType="pubmed">32498529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang E, Hou YZ, Mao JY, Wang JY, Zhao ZQ. Effect of complementary treatment of Chinese drugs on myocardial perfusion patients with acute myocardial infarction after coronary intervention: a systematic review. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2014;34(12):1425&#x2013;1431.
</Citation><ArticleIdList><ArticleId IdType="pubmed">25632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Vong CT, Chen H, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. <i>Chin Med</i>. 2019;14:48. doi: 10.1186/s13020-019-0270-9
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13020-019-0270-9</ArticleId><ArticleId IdType="pmc">PMC6836491</ArticleId><ArticleId IdType="pubmed">31719837</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Hong D, Wang AY, et al. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovasc Disord</i>. 2019;19(1):87. doi: 10.1186/s12872-019-1054-y
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-019-1054-y</ArticleId><ArticleId IdType="pmc">PMC6454772</ArticleId><ArticleId IdType="pubmed">30961544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhou L, Yin W, Li D, Hu C, Zuo X. Clinical efficacy of Danhong injection in preventing contrast-induced acute kidney injury based on propensity score matching method. <i>Zhong Nan Da Xue Xue Bao Yi Xue Ban</i>. 2020;45(10):1193&#x2013;1198. doi: 10.11817/j.issn.1672-7347.2020.190191
</Citation><ArticleIdList><ArticleId IdType="doi">10.11817/j.issn.1672-7347.2020.190191</ArticleId><ArticleId IdType="pubmed">33268580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Lin Y, Li YJ, Gao S. Efficacy of short-term cordyceps sinensis for prevention of contrast-induced nephropathy in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. <i>Int J Clin Exp Med</i>. 2014;7(12):5758&#x2013;5764.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307550</ArticleId><ArticleId IdType="pubmed">25664103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Niu LL, Zhu MJ, Zhu CL. Chinese herbs prevented and treated radiographic contrast nephropathy after percutaneous coronary intervention: an analysis of mechanism. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2016;36(8):991&#x2013;993.
</Citation><ArticleIdList><ArticleId IdType="pubmed">30640997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Huang C, Wang M, Kong X, Liu G, Wang J. Correlation analysis between traditional Chinese medicine syndromes and gastrointestinal bleeding after percutaneous coronary intervention. <i>Evid Based Complement Alternat Med</i>. 2018;2018(1):7356546. doi: 10.1155/2018/7356546
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7356546</ArticleId><ArticleId IdType="pmc">PMC6000832</ArticleId><ArticleId IdType="pubmed">29955236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Huang C, Kong X, et al. A randomized double-blind placebo-controlled trial to evaluate prophylactic effect of traditional Chinese medicine supplementing Qi and Hemostasis formula on gastrointestinal bleeding after percutaneous coronary intervention in patients at high risks. <i>Evid Based Complement Alternat Med</i>. 2018;2018(1):3852196. doi: 10.1155/2018/3852196
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3852196</ArticleId><ArticleId IdType="pmc">PMC6215574</ArticleId><ArticleId IdType="pubmed">30420892</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YJ, Xie Y, Zhao GL, et al. Oral Chinese herbal medicine for depressive disorder in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Chin J Integr Med</i>. 2020;26(8):617&#x2013;623. doi: 10.1007/s11655-019-2702-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-019-2702-x</ArticleId><ArticleId IdType="pubmed">31222629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. <i>Chin J Integr Med</i>. 2011;17(9):669&#x2013;674. doi: 10.1007/s11655-011-0843-7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-011-0843-7</ArticleId><ArticleId IdType="pubmed">21910067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng GH, Liu JP, Chu JF, Mei L, Chen HY. Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease. <i>Cochrane Database Syst Rev</i>. 2013;2013:D9581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11246721</ArticleId><ArticleId IdType="pubmed">23728695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Xiao Y, Chen M, et al. A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials. <i>Biosci Rep</i>. 2018;38(5). doi: 10.1042/BSR20180973</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20180973</ArticleId><ArticleId IdType="pmc">PMC6435456</ArticleId><ArticleId IdType="pubmed">30143584</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Wang P, Du J, et al. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial. <i>Pharmacol Res</i>. 2020;158:104883. doi: 10.1016/j.phrs.2020.104883
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104883</ArticleId><ArticleId IdType="pubmed">32446979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SL, Wang CL, Wang PL, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C Trial): an open-label randomized controlled, multicenter study. <i>Evid Based Complement Alternat Med</i>. 2013;2013:741518. doi: 10.1155/2013/741518
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/741518</ArticleId><ArticleId IdType="pmc">PMC3713597</ArticleId><ArticleId IdType="pubmed">23935679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DW, Wang SL, Wang PL, et al. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention. <i>J Ethnopharmacol</i>. 2020;248:112354. doi: 10.1016/j.jep.2019.112354
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2019.112354</ArticleId><ArticleId IdType="pubmed">31689480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SL, Wang CL, Wang PL, Xu H, Chen KJ, Shi DZ. Chinese herbal medicines might improve the long-term clinical outcomes in patients with acute coronary syndrome after percutaneous coronary intervention: results of a decision-analytic Markov model. <i>Evid Based Complement Alternat Med</i>. 2015;2015:639267. doi: 10.1155/2015/639267
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/639267</ArticleId><ArticleId IdType="pmc">PMC4606398</ArticleId><ArticleId IdType="pubmed">26495019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CL, Shi DZ, Wang Q, Wang SL. Assessing Chinese herbal medicines for benefiting qi and activating blood circulation in treating unstable angina based on Markov model: a long-term clinical effectiveness exploration. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2014;34(4):406&#x2013;411.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24812893</ArticleId></ArticleIdList></Reference><Reference><Citation>Du JP, Wang CL, Wang PL, et al. Efficacy of Chinese herbs for supplementing Qi and activating blood circulation on patients with acute coronary syndrome and type 2 diabetes mellitus after percutaneous coronary intervention: a clinical observation. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2015;35(5):563&#x2013;567.
</Citation><ArticleIdList><ArticleId IdType="pubmed">26159020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao S, Wang L, Zhao X, et al. Efficacy of sodium tanshinone IIA sulfonate in patients with Non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from a multicentre, controlled, randomized trial. <i>Cardiovasc Drugs Ther</i>. 2021;35(2):321&#x2013;329. doi: 10.1007/s10557-020-07077-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07077-8</ArticleId><ArticleId IdType="pubmed">32940893</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, Chen T, Deng B, et al. Effects on Suxiao Jiuxin pills in the treatment of patients with acute coronary syndrome undergoing early percutaneous coronary intervention: a multicenter randomized double-blind placebo-controlled trial. <i>J Altern Complement Med</i>. 2020;26(11):1055&#x2013;1063. doi: 10.1089/acm.2020.0014
</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/acm.2020.0014</ArticleId><ArticleId IdType="pubmed">32716206</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai QQ, Shi ZF, Hu JY, et al. Meta-analysis of effect of Qishen Yiqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention. <i>Zhongguo Zhong Yao Za Zhi</i>. 2021;46(6):1498&#x2013;1510. doi: 10.19540/j.cnki.cjcmm.20200618.501
</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20200618.501</ArticleId><ArticleId IdType="pubmed">33787149</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao C, Fu XH, Yuan JQ, et al. Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention. <i>Cochrane Database Syst Rev</i>. 2015;2015:D10237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11195010</ArticleId><ArticleId IdType="pubmed">25994229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Xia J, Feng R, et al. Randomized controlled clinical study on Yiqi Liangxue Shengji prescription for intervention cardiac function of acute myocardial infarction with ischemia-reperfusion injury. <i>Medicine</i>. 2021;100(10):e24944. doi: 10.1097/MD.0000000000024944
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024944</ArticleId><ArticleId IdType="pmc">PMC7969256</ArticleId><ArticleId IdType="pubmed">33725857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Tian G, Shi Z, et al. Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial. <i>Trials</i>. 2020;21(1):48. doi: 10.1186/s13063-019-3947-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-019-3947-6</ArticleId><ArticleId IdType="pmc">PMC6950857</ArticleId><ArticleId IdType="pubmed">31915046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YS, Mao S, Guo LH, Gao XY, Zou X, Zhang MZ. Effect of Tongguan Capsules () on restenosis after coronary stent implantation: study protocol for a randomized controlled trial. <i>Chin J Integr Med</i>. 2021;27(1):16&#x2013;23. doi: 10.1007/s11655-020-2722-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-020-2722-6</ArticleId><ArticleId IdType="pubmed">32335860</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Li X, Zhang H, et al. China Tongxinluo study for myocardial protection in patients with acute myocardial infarction (CTS-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. <i>Am Heart J</i>. 2020;227:47&#x2013;55. doi: 10.1016/j.ahj.2020.06.011
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.06.011</ArticleId><ArticleId IdType="pmc">PMC7305744</ArticleId><ArticleId IdType="pubmed">32679281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Z, Li H, Li K. Effects of Tongxinluo capsule on 30 cases of acute myocardial infarction after percutaneous coronary intervention. <i>Chin J Exp Traditional Med Formulae</i>. 2014;20:5.</Citation></Reference><Reference><Citation>Zhang L, Li Y, Yang BS, et al. A multicenter, randomized, double-blind, and placebo-controlled study of the effects of tongxinluo capsules in acute coronary syndrome patients with high on-treatment platelet reactivity. <i>Chin Med J</i>. 2018;131(5):508&#x2013;515. doi: 10.4103/0366-6999.226064
</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.226064</ArticleId><ArticleId IdType="pmc">PMC5850665</ArticleId><ArticleId IdType="pubmed">29483383</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang Y, Wang L, et al. Effects of dual-dose clopidogrel, clopidogrel combined with tongxinluo capsule, and ticagrelor on patients with coronary heart disease and CYP2C19*2 gene mutation after percutaneous coronary interventions (PCI). <i>Med Sci Monit</i>. 2017;23:3824&#x2013;3830. doi: 10.12659/MSM.903054
</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.903054</ArticleId><ArticleId IdType="pmc">PMC5555704</ArticleId><ArticleId IdType="pubmed">28783717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge CJ, Yuan F, Feng LX, et al. Clinical effect of Maixuekang Capsule on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention. <i>Chin J Integr Med</i>. 2014;20(2):88&#x2013;93. doi: 10.1007/s11655-013-1580-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-013-1580-x</ArticleId><ArticleId IdType="pubmed">24338186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Wu XY, Wu HX, Wang H. A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism. <i>Chin J Integr Med</i>. 2014;20(12):894&#x2013;902. doi: 10.1007/s11655-014-2023-z
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-014-2023-z</ArticleId><ArticleId IdType="pubmed">25428337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q, Su J, Zhu K, Yang S, Zhu H, Yu J. The effect of Xuefu Zhuyu decoction on clopidogrel resistance and its association with the P2Y12 Gene polymorphisms and promoter DNA methylation. <i>Pak J Pharm Sci</i>. 2019;32(6):2565&#x2013;2572.
</Citation><ArticleIdList><ArticleId IdType="pubmed">31969287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HC, Liu W, Yuan HT, Tang YS. Salvia Miltiorrhiza reduces plasma levels of asymmetric ADMA in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2014;34(12):1436&#x2013;1439.
</Citation><ArticleIdList><ArticleId IdType="pubmed">25632741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao PX, Jiang S. Effect of danhong injection on ET-1, sP-sel, and hs-CRP in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2011;31(1):11&#x2013;14.
</Citation><ArticleIdList><ArticleId IdType="pubmed">21434335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang FY, Sun LP, Yang J. Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2011;31(12):1607&#x2013;1610.
</Citation><ArticleIdList><ArticleId IdType="pubmed">22384544</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin YY, Gao H, Zhang XY, Ai H, Zhu XL, Wang J. Shenfu Injection () inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock. <i>Chin J Integr Med</i>. 2017;23(3):170&#x2013;175. doi: 10.1007/s11655-016-2749-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-016-2749-x</ArticleId><ArticleId IdType="pubmed">28028723</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng S, Wang LS, Huang ZQ, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. <i>Clin Exp Pharmacol Physiol</i>. 2012;39(5):406&#x2013;411. doi: 10.1111/j.1440-1681.2012.05670.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1681.2012.05670.x</ArticleId><ArticleId IdType="pubmed">22220931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Zhu J, Liu Z, et al. Detoxification and activating blood circulation decoction reduces restenosis involving the TLR4/NF-&#x3ba;B pathway after balloon injury. <i>Prostaglandins Other Lipid Mediat</i>. 2019;140:1&#x2013;08. doi: 10.1016/j.prostaglandins.2018.11.002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prostaglandins.2018.11.002</ArticleId><ArticleId IdType="pubmed">30453089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Zhao X. Panaxquin quefolium diolsaponins dose-dependently inhibits the proliferation of vascular smooth muscle cells by downregulating proto-oncogene expression. <i>Indian J Pharmacol</i>. 2013;45(5):483&#x2013;489. doi: 10.4103/0253-7613.117772
</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0253-7613.117772</ArticleId><ArticleId IdType="pmc">PMC3793520</ArticleId><ArticleId IdType="pubmed">24130384</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Long L, Zhang N, Liu Y. Inhibitory effects of hydroxysafflor yellow A on PDGF&#x2011;BB&#x2011;induced proliferation and migration of vascular smooth muscle cells via mediating Akt signaling. <i>Mol Med Rep</i>. 2014;10(3):1555&#x2013;1560. doi: 10.3892/mmr.2014.2336
</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2336</ArticleId><ArticleId IdType="pubmed">24939805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca MP, Morrow DA. SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiol</i>. 2009;5(5):435&#x2013;442. doi: 10.2217/fca.09.27
</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca.09.27</ArticleId><ArticleId IdType="pubmed">19715408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Tang Y, Cai H, et al. Treatment of Danhong injection combined with Naoxintong capsule in acute coronary syndrome patients undergoing PCI operation: study for a randomized controlled and double-blind trial. <i>Evid Based Complement Alternat Med</i>. 2018;2018(1):8485472. doi: 10.1155/2018/8485472
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/8485472</ArticleId><ArticleId IdType="pmc">PMC5863299</ArticleId><ArticleId IdType="pubmed">29707035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Chen T, Wang T, et al. Tongmai Yangxin pill reduces myocardial No-reflow via endothelium-dependent NO-cGMP signaling by activation of the cAMP/PKA pathway. <i>J Ethnopharmacol</i>. 2021;267:113462. doi: 10.1016/j.jep.2020.113462
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113462</ArticleId><ArticleId IdType="pubmed">33058924</ArticleId></ArticleIdList></Reference><Reference><Citation>He GX, Xie J, Jiang H, Tan W, Xu B. Effects of Qishen Yiqi Dripping Pills () in reducing myocardial injury and preserving microvascular function in patients undergoing elective percutaneous coronary intervention: a pilot randomized study. <i>Chin J Integr Med</i>. 2018;24(3):193&#x2013;199. doi: 10.1007/s11655-017-2955-1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-017-2955-1</ArticleId><ArticleId IdType="pubmed">28470563</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu QR, Liu HX, Xing WL, et al. Effect of Danhong Injection () on improving coronary microcirculation injury after percutaneous coronary intervention. <i>Chin J Integr Med</i>. 2021;27(6):455&#x2013;460. doi: 10.1007/s11655-021-2853-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-021-2853-4</ArticleId><ArticleId IdType="pubmed">33433847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JQ, He GX, Pan CX, et al. Effect of anxin granules combined with tirofiba on patients with acute myocardial infarction after elective percutaneous coronary intervention. <i>Zhongguo Zhong Yao Za Zhi</i>. 2014;39(5):920&#x2013;924.
</Citation><ArticleIdList><ArticleId IdType="pubmed">25204191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Wang H, Fan G, et al. Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. <i>Phytomedicine</i>. 2019;61:152850. doi: 10.1016/j.phymed.2019.152850
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2019.152850</ArticleId><ArticleId IdType="pubmed">31035054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Zhu CL, Zhang MZ. Effect of tongguan capsule on the number of endothelial progenitor cells in the peripheral blood of patients with coronary artery disease after PCI. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2013;33(7):873&#x2013;877.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24063204</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu DP, Zou DZ, Qiu HL, Wu HL. Traditional Chinese medicine ShenZhuGuanXin granules mitigate cardiac dysfunction and promote myocardium angiogenesis in myocardial infarction rats by upregulating PECAM-1/CD31 and VEGF expression. <i>Evid Based Complement Alternat Med</i>. 2017;2017(1):5261729. doi: 10.1155/2017/5261729
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5261729</ArticleId><ArticleId IdType="pmc">PMC5512036</ArticleId><ArticleId IdType="pubmed">28757887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan R, Wang Y, Cong WH, Chen KJ. Treatment of cardiovascular disease with Xiongshao capsule. <i>Zhongguo Zhong Yao Za Zhi</i>. 2017;42(4):640&#x2013;643. doi: 10.19540/j.cnki.cjcmm.2017.0017
</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.2017.0017</ArticleId><ArticleId IdType="pubmed">28959830</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian JF, Li JD, Lei Y. Clinical features of acute myocardial infarction inpatients in 26 level three class A Chinese medicine hospitals in China and the investigation of treatment. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2012;32(3):329&#x2013;332.
</Citation><ArticleIdList><ArticleId IdType="pubmed">22686077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou JB, Zhang XF, Wang J, et al. The therapeutic efficacy of Danhong injection combined with percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis. <i>Front Pharmacol</i>. 2018;9:550. doi: 10.3389/fphar.2018.00550
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00550</ArticleId><ArticleId IdType="pmc">PMC5994407</ArticleId><ArticleId IdType="pubmed">29915535</ArticleId></ArticleIdList></Reference><Reference><Citation>Zi M, Li R, Lu F, et al. Clinical study for safety evaluation of GXN tablets combined with aspirin in long-term treatment of coronary heart disease. <i>Evid Based Complement Alternat Med</i>. 2021;2021:6658704. doi: 10.1155/2021/6658704
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6658704</ArticleId><ArticleId IdType="pmc">PMC8205569</ArticleId><ArticleId IdType="pubmed">34211572</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang J. Blood stasis syndrome of coronary heart disease: a perspective of modern medicine. <i>Chin J Integr Med</i>. 2014;20:300&#x2013;306. doi: 10.1007/s11655-013-1332-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-013-1332-3</ArticleId><ArticleId IdType="pubmed">23893237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi RX, Chen KJ, Shi DZ, Li LZ. Diagnostic standard evaluation of Chinese medicine syndrome for coronary heart disease patients after percutaneous coronary intervention. <i>Zhongguo Zhong Xi Yi Jie He Za Zhi</i>. 2013;33(8):1036&#x2013;1041.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24325049</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z, Zhao C, Hu J, et al. The application of traditional Chinese medicine injection on patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. <i>Evid Based Complement Alternat Med</i>. 2020;2020(1):3834128. doi: 10.1155/2020/3834128
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3834128</ArticleId><ArticleId IdType="pmc">PMC7254090</ArticleId><ArticleId IdType="pubmed">32508947</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. <i>Cancer Med</i>. 2019;8(5):1958&#x2013;1975. doi: 10.1002/cam4.2108
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2108</ArticleId><ArticleId IdType="pmc">PMC6536969</ArticleId><ArticleId IdType="pubmed">30945475</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Sun H, Zhang A, Yan G, Wang XJ. Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines. <i>Pharmacol Ther</i>. 2020;216:107680. doi: 10.1016/j.pharmthera.2020.107680
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107680</ArticleId><ArticleId IdType="pmc">PMC7500400</ArticleId><ArticleId IdType="pubmed">32956722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>